Carbidopa; Levodopa Patent Expiration
Carbidopa; Levodopa is Used for treating Parkinson's disease and related conditions such as post-encephalitic parkinsonism and parkinsonism from carbon monoxide or manganese intoxication. It was first introduced by Organon Llc A Sub Of Organon And Co
Carbidopa; Levodopa Patents
Given below is the list of patents protecting Carbidopa; Levodopa, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Crexont | US11986449 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12109185 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12194150 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12201596 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12263148 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12263149 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12295931 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12303481 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Crexont | US12303482 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
| Dhivy | US11033521 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
| Dhivy | US11439613 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
| Dhivy | US11819485 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
| Crexont | US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12128141 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12178918 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12178919 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12274793 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Crexont | US12303605 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
| Rytary | US8377474 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US8454998 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US8557283 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US9089607 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US9089608 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US9463246 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US9533046 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US9901640 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
| Rytary | US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May 29, 2022
(Expired) | Impax |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Carbidopa; Levodopa's patents.
Latest Legal Activities on Carbidopa; Levodopa's Patents
Given below is the list recent legal activities going on the following patents of Carbidopa; Levodopa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9533046 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9463246(Litigated) |
| Email Notification Critical
| 24 May, 2023 | US8377474(Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical
| 24 May, 2023 | US8377474(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089607(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089608(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Aug, 2021 | US9901640 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Mar, 2021 | US8557283(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Sep, 2020 | US8454998(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Aug, 2020 | US8377474(Litigated) |
Carbidopa; Levodopa's Family Patents
